Pfizer Inc. $PFE Stake Lessened by Guggenheim Capital LLC

Key Points

• Guggenheim Capital LLC reduced its holdings in Pfizer Inc. by 5.9%, owning 1,172,927 shares after selling 74,096 shares, valuing their stake at approximately $29.7 million.
• Analysts have recently updated their price targets for Pfizer, with Goldman Sachs raising the target from $25.00 to $27.00, maintaining a "neutral" rating, while Redburn Atlantic cut their target from $29.00 to $27.00.
• Pfizer declared a quarterly dividend of $0.43 per share, resulting in an annualized dividend yield of 6.9%, with a dividend payout ratio of 91.49%.

Guggenheim Capital LLC lowered its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 5.9% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,172,927 shares of the biopharmaceutical company's stock after selling 74,096 shares during the period. Guggenheim Capital LLC's holdings in Pfizer were worth $29,722,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of PFE. Clarity Asset Management Inc. purchased a new stake in shares of Pfizer in the fourth quarter valued at $27,000. Gould Capital LLC raised its holdings in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. purchased a new stake in shares of Pfizer during the first quarter worth $27,000. North Capital Inc. purchased a new stake in shares of Pfizer during the first quarter worth $28,000. Finally, Bayforest Capital Ltd purchased a new stake in shares of Pfizer during the first quarter worth $28,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on PFE shares. Redburn Atlantic cut their price objective on Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a report on Wednesday, April 30th. UBS Group increased their price objective on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. The Goldman Sachs Group increased their price objective on Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Wolfe Research increased their price objective on Pfizer from $22.00 to $23.00 and gave the stock an "underperform" rating in a report on Wednesday, April 30th. Finally, Leerink Partners lowered their target price on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a research report on Wednesday, April 30th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Pfizer currently has an average rating of "Hold" and a consensus target price of $28.12.

Pfizer Trading Down 0.7%

Shares of NYSE:PFE opened at $24.97 on Wednesday. The company has a market cap of $141.94 billion, a P/E ratio of 13.28, a P/E/G ratio of 0.89 and a beta of 0.52. The stock's 50-day moving average is $24.74 and its 200-day moving average is $24.39. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm's revenue was up 10.3% compared to the same quarter last year. During the same period last year, the business posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is currently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.